Skip to main content
Top
Published in: Journal of Neurology 10/2017

01-10-2017 | Neurological Update

Neurological complications of Behçet’s syndrome

Author: D. P. Kidd

Published in: Journal of Neurology | Issue 10/2017

Login to get access

Abstract

In this review of the neurological complications of Behçet’s syndrome, the clinical features and epidemiology of the systemic disease are summarised before a discussion of the neurological syndromes which may develop is made. Neurological involvement occurs in 9% of cases, and is equally prevalent in each geographical area. Vascular complications occur in 14%, in whom thrombosis of the venous sinuses or cerebral veins occurs, and intracranial hypertension, venous infarction and parenchymal haemorrhage may develop. There is a correlation with the prevalence of peripheral venous thrombosis. Concurrent inflammatory disease of the brain is most uncommon. Inflammation may affect any part of the central nervous system, but most commonly involves a subacute meningoencephalitis of the brainstem and diencephalon. Inflammatory lesions elsewhere in the brain and in the spinal cord may occur, and tumefactive lesions may arise from the diencephalon. Cognitive dysfunction and affective symptoms, including psychosis, may occur, and there are high levels of anxiety and fatigue which are related to the severity of the systemic disease, all of which are more severe in those with neurological involvement. Imaging shows enhancing lesions which often disappear after treatment, but atrophy is common. The CSF is active when there is a meningoencephalitis, and oligoclonal bands do not occur. Treatment is with steroids and immunosuppression. Those with treatment resistant disease respond to biological agents, including TNF alpha, IL-1 and IL-6 antagonists.
Literature
1.
go back to reference Yazici H, Fresko I, Yurdakul S (2007) Behçet’s syndrome: disease manifestations, management and advances in treatment. Nat Clin Pract Rheumatol 3:148–155CrossRefPubMed Yazici H, Fresko I, Yurdakul S (2007) Behçet’s syndrome: disease manifestations, management and advances in treatment. Nat Clin Pract Rheumatol 3:148–155CrossRefPubMed
2.
go back to reference Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRefPubMed Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRefPubMed
3.
go back to reference Zierhut M, Abu El-Asrar AM, Bodaghi B, Tugal-Tutkun I (2014) Therapy of ocular Behçet disease. Ocul Immunol Inflamm 22:64–766CrossRefPubMed Zierhut M, Abu El-Asrar AM, Bodaghi B, Tugal-Tutkun I (2014) Therapy of ocular Behçet disease. Ocul Immunol Inflamm 22:64–766CrossRefPubMed
4.
go back to reference Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H (2014) Vascular involvement in syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford) 53:2018–2022CrossRef Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H (2014) Vascular involvement in syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford) 53:2018–2022CrossRef
5.
go back to reference Ambrose N, Pierce IT, Gatehouse PD, Haskard DO, Firmin DN (2014) Magnetic resonance imaging of vein wall thickness in patients with Behçet’s syndrome. Clin Exp Rheumatol 32(4 Suppl 84):S99–S102PubMed Ambrose N, Pierce IT, Gatehouse PD, Haskard DO, Firmin DN (2014) Magnetic resonance imaging of vein wall thickness in patients with Behçet’s syndrome. Clin Exp Rheumatol 32(4 Suppl 84):S99–S102PubMed
6.
go back to reference Mehta P, Laffan M, Haskard DO (2010) Thrombosis and Behçet’s syndrome in non-endemic regions. Rheumatology (Oxford) 49(11):2003–2004CrossRef Mehta P, Laffan M, Haskard DO (2010) Thrombosis and Behçet’s syndrome in non-endemic regions. Rheumatology (Oxford) 49(11):2003–2004CrossRef
7.
go back to reference Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR (1999) Behçet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54:213–220CrossRefPubMed Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR (1999) Behçet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54:213–220CrossRefPubMed
8.
go back to reference Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A (2012) Relationships of HLA-B51 or B5 genotype with Behçet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford) 51:887–900CrossRef Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A (2012) Relationships of HLA-B51 or B5 genotype with Behçet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford) 51:887–900CrossRef
9.
go back to reference Ugurlu N, Bozkurt S, Bacanli A, Akman-Karakas A, Uzun S, Alpsoy E (2015) The natural course and factors affecting severity of disease: a single center cohort of 368 patients. Rheum Int 35:2103–2107CrossRef Ugurlu N, Bozkurt S, Bacanli A, Akman-Karakas A, Uzun S, Alpsoy E (2015) The natural course and factors affecting severity of disease: a single center cohort of 368 patients. Rheum Int 35:2103–2107CrossRef
10.
go back to reference Al-Araji A, Kidd DP (2009) Neuro-Behçet’s disease: epidemiology, clinical characteristics and management. Lancet Neurol 8:192–204CrossRefPubMed Al-Araji A, Kidd DP (2009) Neuro-Behçet’s disease: epidemiology, clinical characteristics and management. Lancet Neurol 8:192–204CrossRefPubMed
12.
go back to reference Wechsler B, Vidailhet M, Piette JC, Bousser MG, Dell Isola B, Blétry O, Godeau P (1992) Cerebral venous thrombosis in Behçet’s disease: clinical study and long-term follow-up of 25 cases. Neurology 42:614–618CrossRefPubMed Wechsler B, Vidailhet M, Piette JC, Bousser MG, Dell Isola B, Blétry O, Godeau P (1992) Cerebral venous thrombosis in Behçet’s disease: clinical study and long-term follow-up of 25 cases. Neurology 42:614–618CrossRefPubMed
13.
go back to reference Aguiar de Sousa D, Mestre T, Ferro JM (2011) Cerebral venous thrombosis in Behçet’s disease: a systematic review. J Neurol 258:719–727CrossRefPubMed Aguiar de Sousa D, Mestre T, Ferro JM (2011) Cerebral venous thrombosis in Behçet’s disease: a systematic review. J Neurol 258:719–727CrossRefPubMed
14.
go back to reference Kidd D (2012) Neurological complications of Behçet’s syndrome. Curr Neurol Neurosci Rep 12(6):675–679CrossRefPubMed Kidd D (2012) Neurological complications of Behçet’s syndrome. Curr Neurol Neurosci Rep 12(6):675–679CrossRefPubMed
15.
go back to reference Hadfield MG, Aydin F, Lippman HR, Sanders KM (1997) Neuro-Behçet’s disease. Clin Neuropathol 16(2):55–60PubMed Hadfield MG, Aydin F, Lippman HR, Sanders KM (1997) Neuro-Behçet’s disease. Clin Neuropathol 16(2):55–60PubMed
16.
go back to reference Hirohata S (2008) Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Sci 267(1–2):41–47CrossRefPubMed Hirohata S (2008) Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Sci 267(1–2):41–47CrossRefPubMed
17.
go back to reference Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behçet’s syndrome. Brain 122(Pt 11):2183–2194CrossRefPubMed Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behçet’s syndrome. Brain 122(Pt 11):2183–2194CrossRefPubMed
18.
go back to reference Akman-Demir G, Serdaroglu P, Tasçi B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 122(Pt 11):2171–2182CrossRefPubMed Akman-Demir G, Serdaroglu P, Tasçi B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 122(Pt 11):2171–2182CrossRefPubMed
19.
go back to reference Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, Koçer N, Yazici H (2001) Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248(2):95–103CrossRefPubMed Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, Koçer N, Yazici H (2001) Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248(2):95–103CrossRefPubMed
20.
go back to reference Al-Araji A, Sharquie K, Al-Rawi Z (2003) Prevalence and patterns of neurological involvement in Behçet’s disease: a prospective study from Iraq. J Neurol Neurosurg Psychiatry 74(5):608–613CrossRefPubMedPubMedCentral Al-Araji A, Sharquie K, Al-Rawi Z (2003) Prevalence and patterns of neurological involvement in Behçet’s disease: a prospective study from Iraq. J Neurol Neurosurg Psychiatry 74(5):608–613CrossRefPubMedPubMedCentral
21.
go back to reference Ideguchi H, Suda A, Takeno M, Kirino Y, Ihata A, Ueda A, Ohno S, Baba Y, Kuroiwa Y, Ishigatsubo Y (2010) Neurological manifestations of Behçet’s disease in Japan: a study of 54 patients. J Neurol 257(6):1012–1020CrossRefPubMed Ideguchi H, Suda A, Takeno M, Kirino Y, Ihata A, Ueda A, Ohno S, Baba Y, Kuroiwa Y, Ishigatsubo Y (2010) Neurological manifestations of Behçet’s disease in Japan: a study of 54 patients. J Neurol 257(6):1012–1020CrossRefPubMed
22.
go back to reference Bilge NŞ, Şaylısoy S, Kaşifoglu T, Korkmaz C (2014) Mass-like lesions as a rare form of neuro-Behçet’s disease: a case report and review of the literature. Eur J Rheumatol 1(1):34–38CrossRefPubMedPubMedCentral Bilge NŞ, Şaylısoy S, Kaşifoglu T, Korkmaz C (2014) Mass-like lesions as a rare form of neuro-Behçet’s disease: a case report and review of the literature. Eur J Rheumatol 1(1):34–38CrossRefPubMedPubMedCentral
23.
go back to reference Oktem-Taner O, Baskan-Kurt B, Gurvit H, Akman-Demir G, Serdaroglu P (1999) Neuropsychological follow up of 12 patients with Neuro-Behçet disease. J Neurol 246:113–119CrossRef Oktem-Taner O, Baskan-Kurt B, Gurvit H, Akman-Demir G, Serdaroglu P (1999) Neuropsychological follow up of 12 patients with Neuro-Behçet disease. J Neurol 246:113–119CrossRef
24.
go back to reference Monastero R, Camardo C, Pipia L, Lopez G, Camarda L, Belmonte V, Ferrante A, Triolo C, Camarda R (2004) Cognitive impairment of Behçet’s disease patients without overt neurological involvement. J Neurol Sci 220:99–104CrossRefPubMed Monastero R, Camardo C, Pipia L, Lopez G, Camarda L, Belmonte V, Ferrante A, Triolo C, Camarda R (2004) Cognitive impairment of Behçet’s disease patients without overt neurological involvement. J Neurol Sci 220:99–104CrossRefPubMed
25.
go back to reference Covaco S, da Silva AN, Pinto P, Continho E, Santos G, Bettencourt A, Pinto C, Goncalves A, Silva S, Gomes F, Corvalho L, Pereira C, Martins B, Correia J, Vasconcelos L (2009) Cognitive function in Behçet’s disease. Ann NY Acad Sci 1173:217–226CrossRef Covaco S, da Silva AN, Pinto P, Continho E, Santos G, Bettencourt A, Pinto C, Goncalves A, Silva S, Gomes F, Corvalho L, Pereira C, Martins B, Correia J, Vasconcelos L (2009) Cognitive function in Behçet’s disease. Ann NY Acad Sci 1173:217–226CrossRef
26.
go back to reference Aydin N, Aydin MD, Deniz O, Kirpinar I (2002) Neuro-Behçet’s disease involving the pons with initial onset of affective symptoms. Eur Arch Psychiatry Clin Neurosci 252:44–46CrossRefPubMed Aydin N, Aydin MD, Deniz O, Kirpinar I (2002) Neuro-Behçet’s disease involving the pons with initial onset of affective symptoms. Eur Arch Psychiatry Clin Neurosci 252:44–46CrossRefPubMed
27.
go back to reference Deniz O, Caykoylu A, Vural G, Albayrak Y, Temel S, Aydin I, Kuloglu M (2009) A case study of neuro-psycho-Behcet’s syndrome presenting with psychotic attack. Clin Neurol Neurosurg 111:87–879CrossRef Deniz O, Caykoylu A, Vural G, Albayrak Y, Temel S, Aydin I, Kuloglu M (2009) A case study of neuro-psycho-Behcet’s syndrome presenting with psychotic attack. Clin Neurol Neurosurg 111:87–879CrossRef
28.
go back to reference Patel P, Steinschneider M, Bonaparth A, Lantos G (2014) Behçet’s disease presenting with acute psychosis in an adolescent. J Child Neurol 29:86–91CrossRef Patel P, Steinschneider M, Bonaparth A, Lantos G (2014) Behçet’s disease presenting with acute psychosis in an adolescent. J Child Neurol 29:86–91CrossRef
29.
go back to reference Talerico R, Palagini L, d’Ascario D, Elefante E, Ferrari C, Stagnaro C, Tani C, Gemignani A, Mauri M, Bombardieri S, Mosca M (2015) Epidemiology and management of neuropsychiatric disorders in Behçet’s syndrome. CNS Drugs 29:189–196CrossRef Talerico R, Palagini L, d’Ascario D, Elefante E, Ferrari C, Stagnaro C, Tani C, Gemignani A, Mauri M, Bombardieri S, Mosca M (2015) Epidemiology and management of neuropsychiatric disorders in Behçet’s syndrome. CNS Drugs 29:189–196CrossRef
30.
go back to reference Ilhan B, Can M, Alibaz-Oner F, Yilmaz-Oner S, Polat-Korkmaz O, Ozen G, Mumcu G, Haradit-Kremers H, Direskinlli H (2016) Fatigue in patients with Behçet’s syndrome: relationship with quality of life, depression, anxiety disability and disease activity. Int J Rheum Dis. doi:10.1111/1756-185X.12839 [Epub ahead of print] PubMed Ilhan B, Can M, Alibaz-Oner F, Yilmaz-Oner S, Polat-Korkmaz O, Ozen G, Mumcu G, Haradit-Kremers H, Direskinlli H (2016) Fatigue in patients with Behçet’s syndrome: relationship with quality of life, depression, anxiety disability and disease activity. Int J Rheum Dis. doi:10.​1111/​1756-185X.​12839 [Epub ahead of print] PubMed
31.
go back to reference Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, Hashimoto T (1997) Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet’s syndrome. Clin Immunol Immunopathol 82(1):12–17CrossRefPubMed Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, Hashimoto T (1997) Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet’s syndrome. Clin Immunol Immunopathol 82(1):12–17CrossRefPubMed
32.
go back to reference Saruhan-Direskeneli G, Yentür SP, Akman-Demir G, Işik N, Serdaroğlu P (2003) Cytokines and chemokines in neuro-Behçet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 145(1–2):127–134CrossRefPubMed Saruhan-Direskeneli G, Yentür SP, Akman-Demir G, Işik N, Serdaroğlu P (2003) Cytokines and chemokines in neuro-Behçet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 145(1–2):127–134CrossRefPubMed
33.
go back to reference Saip S, Siva A, Altintas A, Kiyat A, Seyahi E, Hamuryudan V, Yazici H (2005) Headache in Behçet’s syndrome. Headache 45(7):911–919CrossRefPubMed Saip S, Siva A, Altintas A, Kiyat A, Seyahi E, Hamuryudan V, Yazici H (2005) Headache in Behçet’s syndrome. Headache 45(7):911–919CrossRefPubMed
34.
go back to reference Kidd D (2006) The prevalence of headache in Behçet’s syndrome. Rheumatology (Oxford) 45(5):621–623CrossRef Kidd D (2006) The prevalence of headache in Behçet’s syndrome. Rheumatology (Oxford) 45(5):621–623CrossRef
35.
go back to reference Aykutlu E, Baykan B, Akman-Demir G, Topcular B, Ertas M (2006) Headache in Behçet’s disease. Cephalalgia 26(2):180–186CrossRefPubMed Aykutlu E, Baykan B, Akman-Demir G, Topcular B, Ertas M (2006) Headache in Behçet’s disease. Cephalalgia 26(2):180–186CrossRefPubMed
36.
go back to reference Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B (2016) Long-term efficacy of interferon in severe uveitis associated with Behçet disease. Ocul Immunol Inflamm 19:1–9 Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B (2016) Long-term efficacy of interferon in severe uveitis associated with Behçet disease. Ocul Immunol Inflamm 19:1–9
37.
go back to reference Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, Maruyama K, Nakai K, Hijioka K, Shibuya E, Komae K, Hori J, Ohguro N, Sonoda KH, Mizuki N, Okada AA, Ishibashi T, Goto H, Mochizuki M (2014) Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology 121(10):1877–1884CrossRefPubMed Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, Maruyama K, Nakai K, Hijioka K, Shibuya E, Komae K, Hori J, Ohguro N, Sonoda KH, Mizuki N, Okada AA, Ishibashi T, Goto H, Mochizuki M (2014) Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology 121(10):1877–1884CrossRefPubMed
38.
go back to reference Atida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 4:61–70 Atida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 4:61–70
39.
go back to reference Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D, French Behçet Network (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun 62:67–74CrossRefPubMed Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D, French Behçet Network (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun 62:67–74CrossRefPubMed
40.
go back to reference Vitale A, Rigante D, Lopalco G, Emmi G, Blanco MT, Galeazzi M, Iannone F, Cantarini L (2016) New therapeutic solutions for Behçet’s syndrome. Exp Opin Invest Drugs 25:827–840CrossRef Vitale A, Rigante D, Lopalco G, Emmi G, Blanco MT, Galeazzi M, Iannone F, Cantarini L (2016) New therapeutic solutions for Behçet’s syndrome. Exp Opin Invest Drugs 25:827–840CrossRef
41.
go back to reference Pipitone N, Olivieri I, Padula A et al (2008) Infliximab for the treatment of Neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum 59:285–290CrossRefPubMed Pipitone N, Olivieri I, Padula A et al (2008) Infliximab for the treatment of Neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum 59:285–290CrossRefPubMed
42.
go back to reference Sadreneddini S, Noshad H, Molaeefard M, Noshad R (2008) Treatment of retinal vasculitis in Behçet’s disease with Rituximab. Mod Rheumatol 18:306–308CrossRef Sadreneddini S, Noshad H, Molaeefard M, Noshad R (2008) Treatment of retinal vasculitis in Behçet’s disease with Rituximab. Mod Rheumatol 18:306–308CrossRef
43.
go back to reference Kidd DP (2015) Rituximab is effective in severe treatment-resistant neurological Behçet’s syndrome. J Neurol 262(12):2676–2677CrossRefPubMed Kidd DP (2015) Rituximab is effective in severe treatment-resistant neurological Behçet’s syndrome. J Neurol 262(12):2676–2677CrossRefPubMed
44.
go back to reference Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, Anelli MG, Franceschini R, Menicacci C, Galeazzi M, Selmi C, Rigante D (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet’s disease. Autoimmun Rev 14(1):1–9CrossRefPubMed Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, Anelli MG, Franceschini R, Menicacci C, Galeazzi M, Selmi C, Rigante D (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet’s disease. Autoimmun Rev 14(1):1–9CrossRefPubMed
45.
go back to reference Adimanda O, Pipitone N, Pazzola G, Salvarani C (2015) Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet. Semin Arthritis Rheum 44(4):472–475CrossRef Adimanda O, Pipitone N, Pazzola G, Salvarani C (2015) Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet. Semin Arthritis Rheum 44(4):472–475CrossRef
46.
go back to reference Caso F, Costa L, Rigante D et al (2014) Biological treatments in Behçet’s disease: beyond anti-TNF therapy. Med Inflamm 2014:107421CrossRef Caso F, Costa L, Rigante D et al (2014) Biological treatments in Behçet’s disease: beyond anti-TNF therapy. Med Inflamm 2014:107421CrossRef
Metadata
Title
Neurological complications of Behçet’s syndrome
Author
D. P. Kidd
Publication date
01-10-2017
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 10/2017
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-017-8436-9

Other articles of this Issue 10/2017

Journal of Neurology 10/2017 Go to the issue